keyword
MENU ▼
Read by QxMD icon Read
search

ImmunoPET

keyword
https://www.readbyqxmd.com/read/29759149/functional-imaging-methods-for-assessment-of-minimal-residual-disease-in-multiple-myeloma-current-status-and-novel-immunopet-based-methods
#1
REVIEW
Neeta Pandit-Taskar
Imaging plays a key role in assessment of myeloma. Osteolytic bone lesions are optimally assessed using structural imaging, however the structural changes lag the functional changes in the disease. Functional imaging with fluoro deoxy glucose (FDG) positron emission tomography (PET) computerized tomography (CT) is useful in assessment of high-risk myeloma. FDG PET provides prognostic information and is helpful in monitoring response to therapy. However, it is nonspecific and may not be optimal in assessing treatment response to immunotherapeutic agents...
January 2018: Seminars in Hematology
https://www.readbyqxmd.com/read/29718672/evaluation-of-anti-lgr5-antibodies-by-immunopet-for-imaging-colorectal-tumors-and-development-of-antibody-drug-conjugates
#2
Ali Azhdarinia, Julie Voss, Sukhen C Ghosh, Jo A Simien, Servando Hernandez Vargas, Jie Cui, Wangsheng A Yu, Qingyun Liu, Kendra S Carmon
Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) is highly expressed in colorectal tumors and marks colon cancer stem cells that drive tumor growth and metastasis. Recently, we showed that LGR5 is a promising target for antibody-drug conjugate (ADC) therapy. However, it is important to identify LGR5-positive tumors that would respond ADC treatment. Prior to drug conjugation, we evaluated two different anti-LGR5 monoclonal antibodies (mAbs), 8F2 and 9G5, using 89Zr-immunoPET to select the optimal mAb for ADC development and tumor imaging...
May 2, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29707402/molecularly-specific-detection-of-bacterial-lipoteichoic-acid-for-diagnosis-of-prosthetic-joint-infection-of-the-bone
#3
Julie E Pickett, John M Thompson, Agnieszka Sadowska, Christine Tkaczyk, Bret R Sellman, Andrea Minola, Davide Corti, Antonio Lanzavecchia, Lloyd S Miller, Daniel Lj Thorek
Discriminating sterile inflammation from infection, especially in cases of aseptic loosening versus an actual prosthetic joint infection, is challenging and has significant treatment implications. Our goal was to evaluate a novel human monoclonal antibody (mAb) probe directed against the Gram-positive bacterial surface molecule lipoteichoic acid (LTA). Specificity and affinity were assessed in vitro. We then radiolabeled the anti-LTA mAb and evaluated its effectiveness as a diagnostic imaging tool for detecting infection via immunoPET imaging in an in vivo mouse model of prosthetic joint infection (PJI)...
2018: Bone Research
https://www.readbyqxmd.com/read/29686661/molecular-imaging-of-invasive-pulmonary-aspergillosis-using-immunopet-mri-the-future-looks-bright
#4
REVIEW
Christopher R Thornton
Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease of immuno-compromised humans caused by the ubiquitous environmental mold Aspergillus . Biomarker tests for the disease lack sensitivity and specificity, and culture of the fungus from invasive lung biopsy is slow, insensitive, and undesirable in critically ill patients. A computed tomogram (CT) of the chest offers a simple non-intrusive diagnostic procedure for rapid decision making, and so is used in many hematology units to drive antifungal treatment...
2018: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29684277/immunopet-imaging-of-endogenous-and-transfected-prolactin-receptor-tumor-xenografts
#5
Sarah M Cheal, Shutian Ruan, Darren R Veach, Valerie A Longo, Blesida J Punzalan, Jiong Wu, Edward K Fung, Marcus P Kelly, Jessica R Kirshner, Jason T Giurleo, George Ehrlich, Amy Q Han, Gavin Thurston, William C Olson, Pat B Zanzonico, Steven M Larson, Jorge A Carrasquillo
OBJECTIVE: Antibodies labeled with positron-emitting isotopes have been used for tumor detection, predicting which patients may respond to tumor antigen-directed therapy, and assessing pharmacodynamic effects of drug interventions. Prolactin receptor (PRLR) is overexpressed in breast and prostate cancers and is a new target for cancer therapy. We evaluated REGN2878, an anti-PRLR monoclonal antibody, as an immunoPET reagent. METHODS: REGN2878 was labeled with Zr-89 after conjugation with desferrioxamine B or labeled with I-131/I-124...
April 23, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29682209/-89-zr-nimotuzumab-for-immunopet-imaging-of-epidermal-growth-factor-receptor-i
#6
Rufael Chekol, Viswas Raja Solomon, Elahe Alizadeh, Wendy Bernhard, Darrell Fisher, Wayne Hill, Kris Barreto, John Francis DeCoteau, Angel Casaco Parada, Clarence Ronald Geyer, Humphrey Fonge
Rationale: Epidermal growth factor receptor (EGFR) upregulation is associated with enhanced proliferation and drug resistance in a number of cancers. Nimotuzumab is a humanized monoclonal antibody with high affinity for EGFR. The objective of this study was to determine if 89 Zr-DFO-nimotuzumab could be suitable for human use as a PET probe for quantifying EGFR in vivo . Methods: To evaluate the pharmacokinetics, biodistribution, microPET imaging, radiation dosimetry, and normal tissue toxicity in tumor and non-tumor bearing mice of 89 Zr-desferoxamine-nimotuzumab (89 Zr-DFO-nimotuzumab) of a product prepared under GMP conditions...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29602820/dual-modality-immunopet-and-near-infrared-fluorescence-nirf-imaging-of-pancreatic-cancer-using-an-anti-prostate-cancer-stem-cell-antigen-psca-cys-diabody
#7
Kirstin A Zettlitz, Wen-Ting K Tsai, Scott M Knowles, Naoko Kobayashi, Timothy R Donahue, Robert E Reiter, Anna M Wu
Pancreatic cancer has a high mortality rate due to late diagnosis and the tendency to invade surrounding tissues and metastasize at an early stage. A molecular imaging agent that enables both pre-surgery antigen-specific positron emission tomography (immunoPET) and intra-operative near-infrared fluorescent (NIRF)-guidance could benefit diagnosis, staging and surgical resection of pancreatic cancer, which remains the only curative treatment. Methods: A dually labeled probe was developed based on A2 cys-diabody (A2cDb) targeting the cell surface antigen prostate stem cell antigen (PSCA) that is expressed in a majority of pancreatic cancers...
March 30, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29525125/optimized-anion-exchange-column-isolation-of-zirconium-89-89-zr-from-yttrium-cyclotron-target-method-development-and-implementation-on-an-automated-fluidic-platform
#8
Matthew J O'Hara, Nathaniel J Murray, Jennifer C Carter, Samuel S Morrison
Zirconium-89 (89 Zr), produced by the (p, n) reaction from naturally monoisotopic yttrium (nat Y), is a promising positron emitting isotope for immunoPET imaging. Its long half-life of 78.4 h is sufficient for evaluating slow physiological processes. A prototype automated fluidic system, coupled to on-line and in-line detectors, has been constructed to facilitate development of new 89 Zr purification methodologies. The highly reproducible reagent delivery platform and near-real time monitoring of column effluents allows for efficient method optimization...
April 13, 2018: Journal of Chromatography. A
https://www.readbyqxmd.com/read/29450576/immunopet-imaging-of-cd38-in-murine-lymphoma-models-using-89-zr-labeled-daratumumab
#9
Lei Kang, Dawei Jiang, Christopher G England, Todd E Barnhart, Bo Yu, Zachary T Rosenkrans, Rongfu Wang, Jonathan W Engle, Xiaojie Xu, Peng Huang, Weibo Cai
PURPOSE: CD38 is considered a potential biomarker for multiple myeloma (MM) and has shown a strong link with chronic lymphocytic leukemia due to high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immunoPET imaging with 89 Zr-labeled daratumumab was used for differentiation of CD38 expression in murine lymphoma models to provide a potential non-invasive method for monitoring CD38 in the clinic...
February 15, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29363548/fc-mediated-anomalous-biodistribution-of-therapeutic-antibodies-in-immunodeficient-mouse-models
#10
Sai Kiran Sharma, Andrew Chow, Sebastien Monette, Delphine Vivier, Jacob Pourat, Kimberly J Edwards, Thomas R Dilling, Dalya Abdel-Atti, Brian M Zeglis, John T Poirier, Jason S Lewis
A critical benchmark in the development of antibody-based therapeutics is demonstration of efficacy in preclinical mouse models of human disease, many of which rely on immunodeficient mice. However, relatively little is known about how the biology of various immunodeficient strains impacts the in vivo fate of these drugs. Here we used immunoPET radiotracers prepared from humanized, chimeric, and murine mAbs against four therapeutic oncologic targets to interrogate their biodistribution in four different strains of immunodeficient mice bearing lung, prostate, and ovarian cancer xenografts...
April 1, 2018: Cancer Research
https://www.readbyqxmd.com/read/29356543/site-specifically-labeled-antibody-drug-conjugate-for-simultaneous-therapy-and-immunopet
#11
Pierre Adumeau, Delphine Vivier, Sai Kiran Sharma, Jessica Wang, Terry Zhang, Aimei Chen, Brian J Agnew, Brian M Zeglis
The conjugation of antibodies with cytotoxic drugs can alter their in vivo pharmacokinetics. As a result, the careful assessment of the in vivo behavior, and specifically the tumor-targeting properties, of antibody-drug conjugates represents a crucial step in their development. In order to facilitate this process, we have created a methodology that facilitates the dual labeling of an antibody with both a toxin and a radionuclide for positron emission tomography (PET). To minimize the impact of these modifications, this chemoenzymatic approach leverages strain-promoted azide-alkyne click chemistry to graft both cargoes to the heavy chain glycans of the immuoglobulin's Fc domain...
March 5, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29341222/89-zr-immunopet-companion-diagnostics-and-their-impact-in-clinical-drug-development
#12
REVIEW
Brooke N McKnight, Nerissa T Viola-Villegas
Therapeutic monoclonal antibodies (mAbs) have been used in cancer treatment for 30 years, with around 24 mAb and mAb:drug conjugates approved by the FDA to date. Despite their specificity, efficacy has remained limited, which, in part, derails nascent initiatives towards precision medicine. An image-guided approach to reinforce treatment decisions using immune positron emission tomography (immunoPET) companion diagnostic is warranted. This review provides a general overview of current translational research using Zr-89 immunoPET and opportunities for utilizing and harnessing this tool to its full potential...
January 17, 2018: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/29330552/dosimetry-prediction-for-clinical-translation-of-64-cu-pembrolizumab-immunopet-targeting-human-pd-1-expression
#13
Arutselvan Natarajan, Chirag B Patel, Frezghi Habte, Sanjiv S Gambhir
The immune checkpoint programmed death 1 receptor (PD-1) expressed on some tumor-infiltrating lymphocytes, and its ligand (PD-L1) expressed on tumor cells, enable cancers to evade the immune system. Blocking PD-1 with the monoclonal antibody pembrolizumab is a promising immunotherapy strategy. Thus, noninvasively quantifying the presence of PD-1 expression in the tumor microenvironment prior to initiation of immune checkpoint blockade may identify the patients likely to respond to therapy. We have developed a 64 Cu-pembrolizumab radiotracer and evaluated human dosimetry...
January 12, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29326360/immunopet-in-inflammatory-bowel-disease-imaging-cd4-t-cells-in-a-murine-model-of-colitis
#14
Amanda Christine Freise, Kirstin A Zettlitz, Felix Bergara Salazar, Richard Tavaré, Wen-Ting K Tsai, Arion Hadjioannou, Nora Rozengurt, Jonathan Braun, Anna M Wu
Inflammatory bowel diseases (IBD) in humans are characterized in part by aberrant CD4+ T cell responses. Currently, identification of foci of inflammation within the gut requires invasive procedures such as colonoscopy and biopsy. Molecular imaging with antibody fragment probes could be used to noninvasively monitor cell subsets causing intestinal inflammation. Here, GK1.5 cys-diabody (cDb), an anti-mouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a positron emission tomography (PET) probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD...
January 11, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29291493/-89-zr-for-antibody-labeling-and-in-vivo-studies-a-comparison-between-liquid-and-solid-target-production
#15
Gemma M Dias, Caterina F Ramogida, Julie Rousseau, Nicholas A Zacchia, Cornelia Hoehr, Paul Schaffer, Kuo-Shyan Lin, François Bénard
INTRODUCTION: Zirconium-89 (89 Zr, t1/2 =78.4h) liquid target (LT) production offers an approach to introduce this positron-emitting isotope to cyclotron centres without the need for a separate solid target (ST) production set up. We compared the production, purification, and antibody radiolabeling yields of89 Zr-(LT) and89 Zr-(ST), and assessed the feasibility of89 Zr-(LT) for preclinical PET/CT. METHODS: 89 Zr-(ST) production was performed with an89 Y foil on a TR 19 cyclotron at 13...
March 2018: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29217735/immunopet-in-pontine-glioma-more-than-meets-the-eye
#16
Wim J G Oyen, Chris Jones
No abstract text is available yet for this article.
December 7, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29125731/imaging-pd-l1-expression-with-immunopet
#17
Charles Truillet, Hsueh Ling J Oh, Siok Ping Yeo, Chia-Yin Lee, Loc T Huynh, Junnian Wei, Matthew F L Parker, Collin Blakely, Natalia Sevillano, Yung-Hua Wang, Yuqin S Shen, Victor Olivas, Khaled M Jami, Anna Moroz, Benoit Jego, Emilie Jaumain, Lawrence Fong, Charles S Craik, Albert J Chang, Trever G Bivona, Cheng-I Wang, Michael J Evans
High sensitivity imaging tools could provide a more holistic view of target antigen expression to improve the identification of patients who might benefit from cancer immunotherapy. We developed for immunoPET a novel recombinant human IgG1 (termed C4) that potently binds an extracellular epitope on human and mouse PD-L1 and radiolabeled the antibody with zirconium-89. Small animal PET/CT studies showed that89 Zr-C4 detected antigen levels on a patient derived xenograft (PDX) established from a non-small-cell lung cancer (NSCLC) patient before an 8-month response to anti-PD-1 and anti-CTLA4 therapy...
January 17, 2018: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/28928164/immunopet-of-malignant-and-normal-b-cells-with-89-zr-and-124-i-labeled-obinutuzumab-antibody-fragments-reveals-differential-cd20-internalization-in-vivo
#18
Kirstin A Zettlitz, Richard Tavaré, Scott M Knowles, Kristopher K Steward, John M Timmerman, Anna M Wu
Purpose: The B-cell antigen CD20 provides a target for antibody-based positron emission tomography (immunoPET). We engineered antibody fragments targeting human CD20 and studied their potential as immunoPET tracers in transgenic mice (huCD20TM) and in a murine lymphoma model expressing human CD20. Experimental Design: Anti-CD20 cys-diabody (cDb) and cys-minibody (cMb) based on rituximab and obinutuzumab (GA101) were radioiodinated and used for immunoPET imaging of a murine lymphoma model. Pairwise comparison of obinutuzumab-based antibody fragments labeled with residualizing (89 Zr) versus non-residualizing (124 I) radionuclides by region of interest analysis of serial PET images was conducted both in the murine lymphoma model and in huCD20TM to assess antigen modulation in vivo Results: 124 I-GAcDb and 124 I-GAcMb produced high-contrast immunoPET images of B-cell lymphoma and outperformed the respective rituximab-based tracers...
December 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28915583/n-acetylcysteine-breaks-resistance-to-trastuzumab-caused-by-muc4-overexpression-in-human-her2-positive-bc-bearing-nude-mice-monitored-by-89-zr-trastuzumab-and-18-f-fdg-pet-imaging
#19
Zéna Wimana, Geraldine Gebhart, Thomas Guiot, Bruno Vanderlinden, Denis Larsimont, Gilles Doumont, Gaetan Van Simaeys, Serge Goldman, Patrick Flamen, Ghanem Ghanem
Trastuzumab remains an important drug in the management of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer (BC). Several studies reported resistance mechanisms to trastuzumab, including impaired HER2-accessibility caused by mucin 4 (MUC4). Previously, we demonstrated an increase of Zirconium-89-radiolabeled-trastuzumab ((89)Zr-Trastuzumab) accumulation when MUC4-overexpressing BC-cells were challenged with the mucolytic drug N-Acetylcysteine (NAC). Hereby, using the same approach we investigated whether tumor exposure to NAC would also enhance trastuzumab-efficacy...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28912884/towards-translational-immunopet-mr-imaging-of-invasive-pulmonary-aspergillosis-the-humanised-monoclonal-antibody-jf5-detects-aspergillus-lung-infections-in-vivo
#20
Genna Davies, Anna-Maria Rolle, Andreas Maurer, Philipp R Spycher, Claudia Schillinger, Djamschid Solouk-Saran, Mike Hasenberg, Juliane Weski, Jesper Fonslet, Adrien Dubois, Frederic Boschetti, Franck Denat, Matthias Gunzer, Martin Eichner, Lauren S Ryder, Mikael Jensen, Roger Schibli, Bernd J Pichler, Stefan Wiehr, Christopher R Thornton
Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease of hematological malignancy or bone marrow transplant patients caused by the ubiquitous environmental fungus Aspergillus fumigatus. Current diagnostic tests for the disease lack sensitivity as well as specificity, and culture of the fungus from invasive lung biopsy, considered the gold standard for IPA detection, is slow and often not possible in critically ill patients. In a previous study, we reported the development of a novel non-invasive procedure for IPA diagnosis based on antibody-guided positron emission tomography and magnetic resonance imaging (immunoPET/MRI) using a [(64)Cu]DOTA-labeled mouse monoclonal antibody (mAb), mJF5, specific to Aspergillus...
2017: Theranostics
keyword
keyword
11204
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"